Patent TN-SN00207-A1 (TN)
Title: Antidiabetic formulation and method
Inventor: BETH ANNE PIPER
IPC: A61P1/00
Filed: 2000-10-27
Abstract: ANTIDIABETIC FORMULATION AND METHOD :A LOW DOSE ANTIDIABETIC PHARMACEUTICAL FORMULATION IS PROVIDED, ESPECIALLY ADAPTED FOR TREATING TYPE II DIABETES IN DRUG NAIVE PATIENTS, WHICH INCLUDES A COMBINATION OF METFORMIN (EMPLOYED IN A REDUCED AMOUNT LESS THAN 800 mg METFORMIN PER DAY) COMPARED TO THAT EMPLOYED IN GENERALLY ACCEPTED MEDICAL PRACTICE) AND AT PEAST ONE OTHER ANTIDIABETIC AGENT SUCH AS A SULFONYLUREA, FOR EXAMPLE, GLYBURIDE, WHICH COMBINATION PROVIDES AT LEAST ABOUT SUBSTANTIALLY EQUIVALENT EFFICACY IN TREATING DIABETES IN DRUG NAIVE PATIENTS, AS DO ANTIDIABETIC FORMULATIONS CONTAINING METFORMIN EMPLOYED IN DOSAGES PRESCRIBED IN GENERALLY ACCEPTED MEDICAL PRACTICE FOR FIRST LINE THERAPY IN TREATING DIABETES, BUT WITH SUBSTANTIALLY REDUCED SIDE EFFECTS, SUCH AS HYPOGLYCEMIA AND/OR GASTROINTESTINAL DISTRESS. A METHOD FOR TREATING DIABETES IN DRUG NAIVE HUMAN PATIENTS IS ALSO PROVIDED EMPLOYING THE ABOVE FORMULATION TO REDUCE INSULIN RESISTANCE AND/OR POST-PRANDIAL GLUCOSE EXCURSION AND/OR HEMOGLOBIN 1Ac, AND/OR INCREASE POST-PRANDIAL INSULIN, THEREBY TREATING THE DIABETES. ANTIDIABETIC FORMULATION AND METHOD :A LOW DOSE ANTIDIABETIC PHARMACEUTICAL FORMULATION IS PROVIDED, ESPECIALLY ADAPTED FOR TREATING TYPE II DIABETES IN DRUG NAIVE PATIENTS, WHICH INCLUDES A COMBINATION OF METFORMIN (EMPLOYED IN A REDUCED AMOUNT LESS THAN 800 mg METFORMIN PER DAY) COMPARED TO THAT EMPLOYED IN GENERALLY ACCEPTED MEDICAL PRACTICE) AND AT PEAST ONE OTHER ANTIDIABETIC AGENT SUCH AS A SULFONYLUREA, FOR EXAMPLE, GLYBURIDE, WHICH COMBINATION PROVIDES AT LEAST ABOUT SUBSTANTIALLY EQUIVALENT EFFICACY IN TREATING DIABETES IN DRUG NAIVE PATIENTS, AS DO ANTIDIABETIC FORMULATIONS CONTAINING METFORMIN EMPLOYED IN DOSAGES PRESCRIBED IN GENERALLY ACCEPTED MEDICAL PRACTICE FOR FIRST LINE THERAPY IN TREATING DIABETES, BUT WITH SUBSTANTIALLY REDUCED SIDE EFFECTS, SUCH AS HYPOGLYCEMIA AND/OR GASTROINTESTINAL DISTRESS. A METHOD FOR TREATING DIABETES IN DRUG NAIVE HUMAN PATIENTS IS ALSO PROVIDED EMPLOYING THE ABOVE FORMULATION TO REDUCE INSULIN RESISTANCE AND/OR POST-PRANDIAL GLUCOSE EXCURSION AND/OR HEMOGLOBIN 1Ac, AND/OR INCREASE POST-PRANDIAL INSULIN, THEREBY TREATING THE DIABETES. ANTIDIABETIC FORMULATION AND METHOD :A LOW DOSE ANTIDIABETIC PHARMACEUTICAL FORMULATION IS PROVIDED, ESPECIALLY ADAPTED FOR TREATING TYPE II DIABETES IN DRUG NAIVE PATIENTS, WHICH INCLUDES A COMBINATION OF METFORMIN (EMPLOYED IN A REDUCED AMOUNT LESS THAN 800 mg METFORMIN PER DAY) COMPARED TO THAT EMPLOYED IN GENERALLY ACCEPTED MEDICAL PRACTICE) AND AT PEAST ONE OTHER ANTIDIABETIC AGENT SUCH AS A SULFONYLUREA, FOR EXAMPLE, GLYBURIDE, WHICH COMBINATION PROVIDES AT LEAST ABOUT SUBSTANTIALLY EQUIVALENT EFFICACY IN TREATING DIABETES IN DRUG NAIVE PATIENTS, AS DO ANTIDIABETIC FORMULATIONS CONTAINING METFORMIN EMPLOYED IN DOSAGES PRESCRIBED IN GENERALLY ACCEPTED MEDICAL PRACTICE FOR FIRST LINE THERAPY IN TREATING DIABETES, BUT WITH SUBSTANTIALLY REDUCED SIDE EFFECTS, SUCH AS HYPOGLYCEMIA AND/OR GASTROINTESTINAL DISTRESS. A METHOD FOR TREATING DIABETES IN DRUG NAIVE HUMAN PATIENTS IS ALSO PROVIDED EMPLOYING THE ABOVE FORMULATION TO REDUCE INSULIN RESISTANCE AND/OR POST-PRANDIAL GLUCOSE EXCURSION AND/OR HEMOGLOBIN 1Ac, AND/OR INCREASE POST-PRANDIAL INSULIN, THEREBY TREATING THE DIABETES. ANTIDIABETIC FORMULATION AND METHOD :A LOW DOSE ANTIDIABETIC PHARMACEUTICAL FORMULATION IS PROVIDED, ESPECIALLY ADAPTED FOR TREATING TYPE II DIABETES IN DRUG NAIVE PATIENTS, WHICH INCLUDES A COMBINATION OF METFORMIN (EMPLOYED IN A REDUCED AMOUNT LESS THAN 800 mg METFORMIN PER DAY) COMPARED TO THAT EMPLOYED IN GENERALLY ACCEPTED MEDICAL PRACTICE) AND AT PEAST ONE OTHER ANTIDIABETIC AGENT SUCH AS A SULFONYLUREA, FOR EXAMPLE, GLYBURIDE, WHICH COMBINATION PROVIDES AT LEAST ABOUT SUBSTANTIALLY EQUIVALENT EFFICACY IN TREATING DIABETES IN DRUG NAIVE PATIENTS, AS DO ANTIDIABETIC FORMULATIONS CONTAINING METFORMIN EMPLOYED IN DOSAGES PRESCRIBED IN GENERALLY ACCEPTED MEDICAL PRACTICE FOR FIRST LINE THERAPY IN TREATING DIABETES, BUT WITH SUBSTANTIALLY REDUCED SIDE EFFECTS, SUCH AS HYPOGLYCEMIA AND/OR GASTROINTESTINAL DISTRESS. A METHOD FOR TREATING DIABETES IN DRUG NAIVE HUMAN PATIENTS IS ALSO PROVIDED EMPLOYING THE ABOVE FORMULATION TO REDUCE INSULIN RESISTANCE AND/OR POST-PRANDIAL GLUCOSE EXCURSION AND/OR HEMOGLOBIN 1Ac, AND/OR INCREASE POST-PRANDIAL INSULIN, THEREBY TREATING THE DIABETES. ANTIDIABETIC FORMULATION AND METHOD :A LOW DOSE ANTIDIABETIC PHARMACEUTICAL FORMULATION IS PROVIDED, ESPECIALLY ADAPTED FOR TREATING TYPE II DIABETES IN DRUG NAIVE PATIENTS, WHICH INCLUDES A COMBINATION OF METFORMIN (EMPLOYED IN A REDUCED AMOUNT LESS THAN 800 mg METFORMIN PER DAY) COMPARED TO THAT EMPLOYED IN GENERALLY ACCEPTED MEDICAL PRACTICE) AND AT PEAST ONE OTHER ANTIDIABETIC AGENT SUCH AS A SULFONYLUREA, FOR EXAMPLE, GLYBURIDE, WHICH COMBINATION PROVIDES AT LEAST ABOUT SUBSTANTIALLY EQUIVALENT EFFICACY IN TREATING DIABETES IN DRUG NAIVE PATIENTS, AS DO ANTIDIABETIC FORMULATIONS CONTAINING METFORMIN EMPLOYED IN DOSAGES PRESCRIBED IN GENERALLY ACCEPTED MEDICAL PRACTICE FOR FIRST LINE THERAPY IN TREATING DIABETES, BUT WITH SUBSTANTIALLY REDUCED SIDE EFFECTS, SUCH AS HYPOGLYCEMIA AND/OR GASTROINTESTINAL DISTRESS. A METHOD FOR TREATING DIABETES IN DRUG NAIVE HUMAN PATIENTS IS ALSO PROVIDED EMPLOYING THE ABOVE FORMULATION TO REDUCE INSULIN RESISTANCE AND/OR POST-PRANDIAL GLUCOSE EXCURSION AND/OR HEMOGLOBIN 1Ac, AND/OR INCREASE POST-PRANDIAL INSULIN, THEREBY TREATING THE DIABETES.